← All trials
NCT04586010
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2020
- Primary completion
- Sep 15, 2024
- Completion date
- Nov 10, 2024
- First posted
- Oct 14, 2020
- Last posted
- Dec 14, 2020
- Enrollment
- 734
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.